Somatus Names New Operations and Finance Executives to Accelerate Nationwide Access to Better Kidney Care
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210929005879/en/
“Ros and Chet are seasoned executives who know what it takes to scale a company and deliver on a mission,” said Dr.
Agboke brings more than 16 years of financial experience in the healthcare space, having spent most of her career with
“I have seen how unmanaged kidney disease can impact both a patient and their family,” said Agboke. “Somatus’ innovative care model not only ensures these patients receive outstanding care, but also improves health equity, contains costs, and drives quality outcomes by focusing on disease prevention. I’m honored to be part of the team leading this transformation.”
Akiri joins Somatus with more than 20 years of experience leading and scaling multi-billion-dollar businesses that operate in complex environments. His background is in a diverse range of high-growth industries and product types. Prior to Somatus, Akiri served as the Chief Operating Officer and President for several globally established and publicly traded companies including
“Kidney disease affects almost 40 million people in the US and many, including myself, are close to someone who has been affected,” said Akiri. “The current models are simply inadequate and not patient-focused. The opportunity to join Somatus and partner with providers nationally to transform outcomes for patients with kidney disease completely aligns with how I want to spend my life’s energy.”
Both Agboke and Akiri joined Somatus in August of 2021.
Somatus partners with leading health plans, health systems, and nephrology and primary care groups to provide integrated care for patients with or at risk of developing kidney disease. As the market leader in value-based kidney care, Somatus' vertically integrated clinical services and technology delay or prevent disease progression, improve quality and care coordination, and increase the use of home dialysis modalities and rates of kidney transplantation. The company is headquartered in